Elucidating these issues would not only help us to deeply understand paclitaxel resistance in ovarian cancer, but also develop a rational therapeutic treatment targeting active CEPB4/CSAG2 axis in paclitaxel-resistant ovarian cancer. This evidence concerns the gene CSAG2 and ovarian carcinoma.